Inotiv (NOTVQ) reported $513M in revenue for fiscal 2025, +4.5% year on year. That ranks #2192 by revenue among 2853 SEC filers and #212 in Healthcare. It posted a net loss of −$68.6M for the same year. Revenue has grown 21.6% a year on average since 2011 ($33.1M then). The fiscal 2025 balance sheet shows $734M in total assets, $12.7M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $513M | +4.5% | FY20252025-09-30 |
| Gross profitGrossProfit | $30.2M | +65.4% | FY20212021-09-30 |
| Operating incomeOperatingIncomeLoss | −$30.9M | +$55.5M | FY20252025-09-30 |
| Net incomeNetIncomeLoss | −$68.6M | +$39.8M | FY20252025-09-30 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$10.5M | −$3.7M | FY20252025-09-30 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $16.6M | −25.5% | FY20252025-09-30 |
| Total assetsAssets | $734M | −5.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $109M | −35.8% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $12.7M | −66.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $0 | −100.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $118M | −$32.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Inotiv, Inc.
- Ticker
- NOTVQ
- SIC classification
- Services-Commercial Physical & Biological Research (8731)
- Fiscal year end
- 09-30
- CIK
- 0000720154
Filings
- 10-QMay 11, 2026Open filing →
- 10-QFeb 9, 2026Open filing →
- 10-KDec 5, 2025Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| AtricureATRC | $535M | −$11.4M |
| Mirum PharmaceuticalsMIRM | $521M | −$23.4M |
| VeracyteVCYT | $517M | $66.4M |
| InotivNOTVQ | $513M | −$68.6M |
| Adma BiologicsADMA | $510M | $147M |
| GlaukosGKOS | $507M | −$188M |
| Starling OncologySTLN | $503M | $60.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Inotiv — Key figures |url=https://companiesranked.com/en/company/inotiv |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Inotiv — Key figures. CompaniesRanked. https://companiesranked.com/en/company/inotivBibTeX
@misc{companiesranked-en-company-inotiv-2026,
author = {{CompaniesRanked}},
title = {{Inotiv — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/inotiv}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-25-055483 · December 5, 2025
{{cite web |title=Inotiv — Key figures — 10-K (0001628280-25-055483) |url=https://www.sec.gov/Archives/edgar/data/720154/000162828025055483/notv-20250930.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2025-12-05}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.